Myriad Genetics, Inc. (NASDAQ:MYGN) received analyst consensus rating of “Hold”

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has earned a consensus rating of “Hold” from five ratings firms, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated coverage on the stock in the last year is $24.20.

Several research firms recently issued reports on MYGN. StockNews.com began coverage on shares of Myriad Genetics in a research report on Thursday, August 17th. They assigned a “hold” rating to the stock. Goldman Sachs Group boosted their target price on shares of Myriad Genetics from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, July 21st. Finally, JPMorgan Chase & Co. cut their target price on shares of Myriad Genetics from $18.00 to $17.00 and set an “underweight” rating on the stock in a research report on Monday, August 7th.

Get our latest report on Myriad Genetics

Institutional inflows and outflows

A number of institutional investors have recently bought and sold shares of the company. Comerica Bank acquired a new position in Myriad Genetics in the second quarter valued at $22,450,000. Teacher Retirement System of The State of Kentucky boosted its holdings in Myriad Genetics by 5.7% in the second quarter. Teacher Retirement System of The State of Kentucky now owns 26,128 shares of the company’s stock worth $606,000 after buying an additional 1,416 shares during the last quarter. Nuveen Asset Management LLC raised its stake in Myriad Genetics by 125.2% in the second quarter. Nuveen Asset Management LLC now owns 496,079 shares of the company’s stock worth $11,499,000 after buying an additional 275,802 shares during the last quarter. State of Tennessee Treasury Department boosted its holdings in Myriad Genetics by 2.1% in the second quarter. State of Tennessee Treasury Department now owns 48,914 shares of the company’s stock valued at $1,134,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Natixis Advisors LP raised its stake in Myriad Genetics by 27.2% in the second quarter. Natixis Advisors LP now owns 138,524 shares of the company’s stock worth $3,211,000 after buying an additional 29,645 shares during the last quarter. Institutional investors and hedge funds own 99.02% of the company’s shares.

Myriad Genetics Trading rose 0.5%

NASDAQ:MYGN opened at $16.70 on Tuesday. The company has a fifty day moving average of $18.49 and a 200 day moving average of $20.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.23, and a current ratio of 1.33. Myriad Genetics has a 52-week low of $13.92 and a 52-week high of $24.21. The company has a market cap of $1.37 billion, a P/E ratio of -5.49 and a beta of 1.78.

Myriad Genetics (NASDAQ:MYGN – Get Your Free Report ) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). Myriad Genetics had a net margin of 35.51% and a return on equity of 9.43%. The company had revenue of $183.50 million for the quarter, compared to analyst estimates of $187.16 million. During the same period last year, the company posted EPS of ($0.06). The company’s quarterly turnover increased by 2.3% compared to the same period last year. equities analysts expect that Myriad Genetics will post -0.61 earnings per share for the current year.

Myriad Genetics Company Profile

(Get a free report

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology and women’s and mental health applications. It also offers the MyRisk Hereditary Cancer Test, a DNA sequencing test to assess hereditary cancer risks; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test that helps guide the treatment of patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer who have deleterious or suspected deleterious germline BRCA variants; and the MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in ovarian cancer patients.

See also

This breaking news alert was created using MarketBeat’s narrative research technology and financial data to provide readers with the fastest and most accurate reporting. MarketBeat editorial staff reviewed this story prior to publication. Please direct any questions or comments about this story to contact@marketbeat.com.

Before you consider Myriad Genetics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and best-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market kicks in … and Myriad Genetics wasn’t on the list.

While Myriad Genetics currently has a “Hold” rating among analysts, the top-rated analysts believe these five stocks are better buys.

Check out five stocks here

MarketBeat analysts have just released their top five short picks for October 2023. Find out which stocks have the highest interest rates and how to trade them. Click the link below to see which companies made the list.

Get this free report